Deutsche Bank analyst George Hill lowered the firm’s price target on GoodRx (GDRX) to $6 from $8 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Holdings: Strategic Growth and Revised Projections Support Buy Rating Despite Short-term Adjustments
- GoodRx downgraded to Outperform from Strong Buy at Raymond James
- Positive Outlook for GoodRx Holdings Amid Strategic Initiatives and Market Expansion Opportunities
- GoodRx Reports Steady Q2 2025 Financial Results
- Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings